Viglya

Regulatory Affairs and Pharmacovigilance services through drug development and post-autorization for the biopharmaceutucial industry

[Viglya @Viglya]

#AEMPS: Cese de comercialización, retirada del mercado y recuperación de las ampollas antiedad Vichy Liftactiv Specialist Peptide-C

https://t.co/Qs6Zrsor22

[Viglya @Viglya]

#EMA: Hydroxyethyl-starch solutions for infusion recommended for suspension from the market

https://t.co/InNAoj3P9D

[Viglya @Viglya]

#FDA Warns of Risks Associated with Non-Invasive Prenatal Screening Tests #pvnewsfda

https://t.co/G0JCVdiyen

[Viglya @Viglya]

#EMA: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 April 2022 #pvnewsema

https://t.co/AKMXV25CDE

[Akron Bio @akronbiotech]

We’re counting down the final days! On April 12, we’ll be opening our new cGMP manufacturing facility designed to deliver the pDNA manufacturing capacity you need. #BioMfgSarasota #Biotech

[Queensland Health @qldhealth]

A Transient Ischaemic Attack is often referred to as a mini stroke. The symptoms are similar, but don’t last as long, usually only a few minutes to an hour or two. 🧠
Discover more about symptoms and causes in our blog: https://t.co/lsCfS3s0j5

[Ashata Dahal 🇳🇵 @AshataDahal]

Together,we can #TakeOnTyphoid. So glad to be a part of the research which is now implemented as a policy. Introduction of #typhoid conjugate vaccine in #Nepal was made possible by support & coordination from @gavi @WHOSEARO @unicef_nepal @mohpnep @WHONepal @OxfordVacGroup

[Oxford Vaccine Group @OxfordVacGroup]

We are incredibly proud of everyone involved in this lifesaving partnership! 🫶

Together we can #TakeOnTyphoid.

[TGA Australia @TGAgovau]

We have issued an infringement notice of $13,320 to Sydney-based company Ferngrove Pharmaceuticals Pty Ltd for alleged contraventions of the Therapeutic Goods Act 1989 in relation to pharmacovigilance (activities monitoring the safety of medicines). 👉 https://t.co/QcodWLke8u

[Viglya @Viglya]

Regulatory information – 0.3% and 5.3% increase in general fees from 1 April 2022 #ranewsema

https://t.co/svOJzIMe9u

[Viglya @Viglya]

EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice,

https://t.co/4R4Eec1kQn

[Viglya @Viglya]

#AEMPS: Boletín mensual de seguridad de la AEMPS sobre medicamentos de uso humano del mes de enero de 2022 #pvnewsaemps

https://t.co/pZCy4rnq3G

[Viglya @Viglya]

#FDA Issues Decisions on Additional E-Cigarette Products

https://t.co/rhIpEUUHwg

[Viglya @Viglya]

#EMA recommends authorisation of COVID-19 medicine Evusheld

https://t.co/LArP2630nX

[Viglya @Viglya]

#FDA Approves First Generic of Symbicort to Treat Asthma and COPD. #ddfdanews

https://t.co/QEJM6gWwIT

[Viglya @Viglya]

#EMA Management Board elects Lorraine Nolan as chair. #raemanews

https://t.co/iEOfWAjVj9

[Viglya @Viglya]

#AEMPS Los problemas de suministro que más afectan al paciente suponen un 0,2% de los casos.

https://t.co/31lZa3XugR

[Viglya @Viglya]

#FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review #pvnewsfda

https://t.co/az6vXaN9OE

[Viglya @Viglya]

Regulation on #EMA’s extended mandate becomes applicable. #ranewsema

https://t.co/Q2Q8iT8Ys4

[Viglya @Viglya]

#EMA: Hydroxyethyl-starch solutions for infusion recommended for suspension from the market

https://t.co/InNAoj3P9D